Dianne Angus
Fortune : 438 455 $ au 30/09/2026
Fortune : 438 455 $ au 30/09/2026
Ms. Dianne Angus is an Independent Non-Executive Director at Cyclopharm Ltd., an Independent Non-Executive Director at Neuren Pharmaceuticals Ltd., a Council Member at Deakin University and a Member at Australian Institute of Co. Directors.
She is on the Board of Directors at Cyclopharm Ltd. and Neuren Pharmaceuticals Ltd. Ms. Angus was previously employed as an Independent Non-Executive Chairman by Argenica Therapeutics Ltd., an Independent Non-Executive Director by Imagion Biosystems Ltd., a Chief Operating Officer by Alterity Therapeutics Ltd., and a Manager-Joint Venture Alliance by Calgene Pacific Ltd. She also served on the board at Dianne Angus & Associates Pty Ltd. She received her undergraduate degree from the University of Melbourne and a graduate degree from Monash University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/03/2026 | 30 000 ( 0,02 % ) | 424 725 $ | 30/09/2026 | |
CYCLOPHARM LIMITED 0,03 % | 12/03/2026 | 43 375 ( 0,03 % ) | 13 730 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| NEUREN PHARMACEUTICALS LIMITED | Directeur/Membre du Conseil | 05/07/2018 |
| CYCLOPHARM LIMITED | Directeur/Membre du Conseil | 10/08/2021 |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Corporate Officer/Principal | - |
Deakin University
Deakin University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Sociétés | Poste | Fin |
|---|---|---|
| ARGENICA THERAPEUTICS LIMITED | Président | 31/12/2025 |
| IMAGION BIOSYSTEMS LIMITED | Directeur/Membre du Conseil | 03/05/2024 |
Dianne Angus & Associates Pty Ltd. | Directeur/Membre du Conseil | 01/08/2002 |
Florigene Ltd.
Florigene Ltd. BiotechnologyHealth Technology Provides genetic modification technology to bridge genetic gaps and deliver improvements to flower species | Corporate Officer/Principal | 01/01/2000 |
| ALTERITY THERAPEUTICS LIMITED | Directeur des opérations | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Neuren Pharmaceuticals Ltd.
Neuren Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Manufactures drugs for neurological disorders | Health Technology |
Cyclopharm Ltd.
Cyclopharm Ltd. Medical SpecialtiesHealth Technology Manufactures and sells medical health care equipments | Health Technology |
Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs | Health Technology |
University of Melbourne
University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Florigene Ltd.
Florigene Ltd. BiotechnologyHealth Technology Provides genetic modification technology to bridge genetic gaps and deliver improvements to flower species | Health Technology |
Monash University
Monash University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deakin University
Deakin University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Commercial Services |
Dianne Angus & Associates Pty Ltd. | |
Imagion Biosystems Ltd.
Imagion Biosystems Ltd. Medical SpecialtiesHealth Technology Develops medical devices | Health Technology |
Argenica Therapeutics Ltd.
Argenica Therapeutics Ltd. BiotechnologyHealth Technology Develops novel neuro protective therapeutics to reduce brain damage | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national